when will eli lilly release retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In ADA 2026: Retatrutide Revolution

Kamakura R, Raza GS, Mkil E, Riikonen J, Kovalainen M, Ueta Y, et al

Interestingly, according to the weight loss and increased IGF-2 levels, patients treated with liraglutide showed changes in adipose tissue distribution with reduction of the visceral adipose tissue, which expresses IGF-2, IGF-2 receptors and IR

In obese subjects without diabetes, SGLT2 inhibitors do not alter the estimated glomerular filtration rate or have any adverse event potentially related to renal impairment or renal failure over a 52-week period [21]

1 Table 1 provides an overview of the key findings on the role of GLP-1 receptor agonists in AUD

Wang K, Liu H, Hu Q, et al

Nguyen, A